261 related articles for article (PubMed ID: 36963566)
21. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
22. New Perspectives on Antimicrobial Agents: Maribavir.
Halpern-Cohen V; Blumberg EA
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0240521. PubMed ID: 35916518
[TBL] [Abstract][Full Text] [Related]
23. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
Jorgenson MR; Descourouez JL; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158
[TBL] [Abstract][Full Text] [Related]
24. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.
El Chaer F; Shah DP; Chemaly RF
Blood; 2016 Dec; 128(23):2624-2636. PubMed ID: 27760756
[TBL] [Abstract][Full Text] [Related]
25. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
26. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Torres-Madriz G; Boucher HW
Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
[TBL] [Abstract][Full Text] [Related]
27. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
Avery RK; Alain S; Alexander BD; Blumberg EA; Chemaly RF; Cordonnier C; Duarte RF; Florescu DF; Kamar N; Kumar D; Maertens J; Marty FM; Papanicolaou GA; Silveira FP; Witzke O; Wu J; Sundberg AK; Fournier M;
Clin Infect Dis; 2022 Sep; 75(4):690-701. PubMed ID: 34864943
[TBL] [Abstract][Full Text] [Related]
28. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
Perrottet N; Manuel O; Lamoth F; Venetz JP; Sahli R; Decosterd LA; Buclin T; Pascual M; Meylan P
BMC Infect Dis; 2010 Jan; 10():2. PubMed ID: 20053269
[TBL] [Abstract][Full Text] [Related]
29. Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients.
Valencia Deray KG; Danziger-Isakov LA; Downes KJ
J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S14-S21. PubMed ID: 38417084
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
[TBL] [Abstract][Full Text] [Related]
31. Maribavir for the Management of Cytomegalovirus in Adult Transplant Recipients: A Review of the Literature and Practical Considerations.
Kleiboeker HL; Descourouez JL; Schulz LT; Mandelbrot DA; Odorico JS; Rice JP; Saddler CM; Smith JA; Jorgenson MR
Ann Pharmacother; 2023 May; 57(5):597-608. PubMed ID: 36003036
[TBL] [Abstract][Full Text] [Related]
32. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
[TBL] [Abstract][Full Text] [Related]
33. Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene.
Leung PYM; Tran T; Testro A; Paizis K; Kwong J; Whitlam JB
Transpl Infect Dis; 2019 Dec; 21(6):e13168. PubMed ID: 31498954
[TBL] [Abstract][Full Text] [Related]
34. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Noble S; Faulds D
Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
[TBL] [Abstract][Full Text] [Related]
35. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
[TBL] [Abstract][Full Text] [Related]
36. Healthcare resource utilization of maribavir versus investigator-assigned therapy in transplant recipients with cytomegalovirus infection refractory (with or without genotypic resistance) to prior treatment: Exploratory analysis of the Phase 3 SOLSTICE trial.
Hirji I; Cocks K; Moreno-Koehler A; Sundberg A
Transpl Infect Dis; 2023 Jun; 25(3):e14064. PubMed ID: 37154528
[TBL] [Abstract][Full Text] [Related]
37. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
38. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
[TBL] [Abstract][Full Text] [Related]
39. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
Maertens J; Cordonnier C; Jaksch P; Poiré X; Uknis M; Wu J; Wijatyk A; Saliba F; Witzke O; Villano S
N Engl J Med; 2019 Sep; 381(12):1136-1147. PubMed ID: 31532960
[TBL] [Abstract][Full Text] [Related]
40. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.
Razonable RR; Humar A
Clin Transplant; 2019 Sep; 33(9):e13512. PubMed ID: 30817026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
